Gastric cancer (GC) is relatively common around the world, mainly in its sporadic form; however, familial aggregation of the disease may be seen in approximately 10% of GC cases \[[@B1]\]. The prevalence of GC in Korea is high, with crude incidence rates in men and women of 86.8 and 41.1 per 100,000 person-years, respectively, in 2012 \[[@B2]\]. Because the stage of GC at the time of detection correlates with prognosis, cancer screening is important for early detection, with nationwide screening programs being enforced for the promotion of cancer screening in Korea \[[@B3]\]. The detection of GC at an early stage has increased. However, genetic causes of GC can be easily overlooked in an area with a high occurrence of stomach cancer, such as Korea, possibly because of the causes being attributed to *Helicobacter pylori* (*H. pylori*) infection, diet, and life style \[[@B4]\].

Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant disorder caused by germline mutation of the cadherin-1 gene (*CDH1*), which encodes the cell-to-cell adhesion protein E-cadherin. Early diagnosis of HDGC is very difficult because the tumor cells begin infiltrating the mucosa while preserving a normal surface epithelium, and visible lesions can rarely be spotted endoscopically \[[@B5]\]. In such cases, recent advances in molecular medicine have not only clarified the carcinogenesis of GC, but have also offered novel approaches regarding GC prevention, diagnosis, and therapeutic intervention \[[@B6]\].

To our knowledge, this is the first report on presymptomatic identification of *CDH1* mutation in a Korean individual with a family history of diffuse GC (DGC). Being exposed to medical information on genetic mutations associated with GC through a newspaper article, a 44-yr-old male visited our genetic counseling clinic for genetic testing of the gene associated with GC. He showed no specific symptoms or anomalous findings on physical examination, as well as no known history of other genetic disorders. His father died of GC at the age of 54; and a year after GC diagnosis at the age of 52, one of his paternal aunts showed terminal-stage GC ([Fig. 1](#F1){ref-type="fig"}). However, histological diagnosis was not known or performed for his father and aunt. To be diagnosed with HDGC, a family should meet the criteria proposed by the International Gastric Cancer Linkage Consortium (IGCLC) \[[@B7]\], which includes the followings: 1) two or more documented cases of DGC in first- or second-degree relatives, with at least one case diagnosed before the age of 50 yr; or 2) three or more cases of documented DGC in first- or second-degree relatives, independent of their ages. Previously, 25-50% of the families fulfilling the criteria for HDGC were shown to have germline mutations in *CDH1* \[[@B7], [@B8]\]. Considering the family history, genetic analysis of the *CDH1* was performed with the patient\'s written informed consent; the analysis did not fulfill the clinical criteria of HDGC as defined by the IGCLC.

Genomic DNA was extracted from the individual\'s peripheral blood leukocytes by using Wizard Genomic DNA Purification kit (Promega, Madison, WI, USA), according to the manufacturer\'s instructions. All the coding exons and flanking intronic regions of *CDH1* were amplified by using the primer sets we designed (available on request). PCR was performed by using a thermal cycler (Model 9700; Applied Biosystems, Foster City, CA, USA). Five microliters of the amplification product was treated with 2 U of shrimp alkaline phosphatase and 10 U exonuclease I (USB Corp., Cleveland, OH, USA). Direct sequencing was per-formed by using BigDye Terminator Cycle Sequencing Ready Reaction Kit and an ABI Prism 3130 Genetic Analyzer (Applied Biosystems). The obtained sequences were analyzed by using the Sequencher program (Gene Codes Corp., Ann Arbor, MI, USA) and were compared with a reference sequence (GenBank accession number NM_004360.3).

The sequencing revealed that he had a known heterozygous mutation in codon 340 of *CDH1*, resulting in an amino acid change from threonine to alanine (c.1018A\>G, p.Thr340Ala) ([Fig. 2](#F2){ref-type="fig"}). Although he showed no specific symptoms such as nausea or dyspepsia, he was recommended intensive endoscopic surveillance and genetic counseling, considering the *CDH1* mutation. For the esophagogastroduodenoscopy (EGD) findings, any macroscopically significant lesion suggesting DGC was not observed in the individual\'s stomach. In addition, chronic active *H. pylori* gastritis was found. An endoscopic biopsy was performed by randomly selecting two sites, including lower and higher parts on the greater curvature of the stomach, but the results showed no abnormal pathological findings.

We informed the individual underwent genetic counseling along with his family members of the possibilities of their mutation status and of their options following the testing. Not all the family members underwent the genetic testing; the individual\'s older brother was found to have the same *CDH1* mutation, identified in our individual. Therefore, they can be considered asymptomatic *CDH1* mutation carriers; they received an explanation on the prophylactic gastrectomy, and then chose to opt for periodic surveillance. Under the surveillance program for screening *CDH1* mutation-positive individuals in our genetic clinics, he and his older brother have annually undergone EGD to ensure that there is no evidence of clinically significant lesions. As of the time of this publication, they are alive and do not show the occurrence of GC, as ascertained by annual endoscopic surveillance for about 5 yr from the time of identification in *CDH1* mutation.

*CDH1*, which is a known tumor suppressor gene, is located on chromosome 16q22.1, and it contains 2.6 kb of coding sequences and 16 exons. To date, approximately 122 *CDH1* germline mutations have been identified \[[@B9]\]. Male and female carriers of a germline *CDH1* mutation have over 80% of lifetime risk of developing DGC, along with a 33-52% increased risk of lobular breast cancer in women \[[@B10], [@B11]\].

In the present study, we identified c.1018A\>G (p.Thr340Ala) located in *CDH1*, which is a known disease-causing mutation as reported in HDGC families in Europe and China \[[@B8], [@B12]\]. In Korea, there have been no previous reports to our knowledge on the identification of c.1018A\>G in a GC-afflicted family, although it has been reported in two patients with ascending colon cancer and sigmoid colon cancer \[[@B13]\]. The functional analysis of the *CDH1* mutation p.Thr340Ala showed that p.Thr340Ala-expressing cells exhibited altered cellular morphology from epithelial to fibroblastic morphotype and presented a highly motile phenotype \[[@B14]\]. In particular, p.Thr340Ala mutation influences cell migration by increasing Rho-GTPase activity \[[@B14]\].

*CDH1*-mutation positive individuals must be surveilled and be given genetic counseling \[[@B7]\]. The consensus reached at an IGCLC workshop was that individuals who test positive for a *CDH1* mutation should be advised to consider prophylactic gastrectomy regardless of any endoscopic findings \[[@B5], [@B7]\]. If individuals with *CDH1* mutation refuse or delay gastrectomy due to choice, surveillance endoscopy should be offered annually in order to ensure that there is no evidence of clinically significant lesions \[[@B7]\].

*CDH1* mutations preferentially affect gastric epithelia, but tumors do occur outside the stomach in HDGC families, at sites including the colon, lung, prostate, salivary glands, pancreas, and appendix \[[@B15], [@B16]\]. Several studies have documented that colorectal cancer is an occasional member of the HDGC disease spectrum \[[@B15], [@B16], [@B17]\], with the recommendation that surveillance colonoscopy should commence in such families for individuals over the age of 40, or those who are 10 yr younger than the youngest person diagnosed with colon cancer \[[@B7]\]. However, the spectrum and frequency of other extra-gastric diseases occurring in in conjunction with HDGC is uncertain, mainly because the number of identified HDGC families is too small to establish significant associations \[[@B15]\]. Further studies are needed to accurately define such extra-gastric malignancies as being a part of the HDGC spectrum of malignancies in individuals with genetically verified HDGC, and to better define the clinical guidelines for screening the malignancies.

The lack of a sensitive screening test for HDGC makes its early diagnosis challenging. However, genetic testing can confirm whether a condition in patient is the result of an inherited syndrome. The identification of *CDH1* mutation in individuals with a family history of GC may provide valuable information for genetic counseling, genetic testing for GC susceptibility, GC risk reduction management for the as-yet unaffected family members, and confirmatory diagnosis of HDGC for the proband \[[@B18]\]. Moreover, as more individuals with HDGC are identified early by genetic screening and undergo prophylactic gastrectomy, longer survival outcomes will effectively unveil additional risks of malignancy at other organ sites \[[@B16], [@B18]\]. However, there is a paucity of research on familial GC, and the effort to identify genetic causes in patients with GC is still unfamiliar to Korean clinicians, with the high prevalence of the GC in Korea making it undesirable \[[@B19], [@B20]\].

To summarize, clinicians should consider the relevance of genetic predisposition with early-onset or familial clustering of GC, irrespective of endoscopic findings showing abnormal gastric mucosa. A proactive attempt to identify familial GC, including genetic counseling and *CDH1* screening, will provide comprehensive management and confirmatory diagnosis of HDGC, in addition to providing new insights into tumor initiation, progression, and metastasis of hereditary GC in Korea.
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